Blinding is intended to limit bias arising from knowledge of treatment in which aspects?

• A. It limits only bias in recruitment.
• B. It has no effect on endpoint assessment.
• C. It is primarily for data analysis.
• D. It aims to limit conscious and unconscious bias in recruitment, allocation, care, endpoint assessment, withdrawals, and data handling.

Answer: (D)

Blinding protects the integrity of a trial by preventing knowledge of which treatment a participant receives from influencing decisions and assessments at several points in the study. When people involved—participants, clinicians, and outcome assessors—don’t know the assignment, it reduces both conscious and unconscious bias that could affect recruitment decisions, how participants are allocated, the care given, how endpoints are measured, how withdrawals and follow-ups are handled, and how data are collected and analyzed. This broad, multi-faceted protection is why the option describing bias limitation in recruitment, allocation, care, endpoint assessment, withdrawals, and data handling is best. It’s not limited to just recruitment or just endpoint assessment, and blinding does impact data handling and analysis as well since knowing the treatment could color data recording or interpretation.